Navigation Links
Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection
Date:11/10/2008


- Gene Signal International, a Biotech Company Registered in

Switzerland, Will Move its Headquarter to the EPFL, in Lausanne,

- Gene Signal is Addressing Various Issues Related to Neovascularisation,

- Gene Signal is Working on a Portfolio of Ophthalmologic Indications,

With One Now in Phase III Trials

- Gene Signal Will Present its Interim Results at the Annual Meeting of

the American Academy of Ophtalmologist in Atlanta, USA, the

Largest Scientific Convention in this Field

Gene Signal, a biotech company registered in Switzerland, is currently starting the Phase III study of GS-101, its most advanced therapeutic ophthalmic solution, for the prevention of corneal graft rejection.

Every year, over 40'000 corneal grafts are performed worldwide to cure or prevent blindness, thus making this procedure the most frequently performed transplant surgery. However, the 5 year failure rate for corneal grafts is currently around 35%. As many other graft procedures, donor grafts are always in limited supply. A failure is even more "wasteful" in this context of long waiting lines (6 months - 2 years).

One of the main reasons for graft failure is the immune response of the body. Normally, the cornea is avascular (i.e. deprived of blood vessels), protecting the donor cornea from being rejected. However, under certain circumstances, new blood vessel creation (neovascularization) occurs, inducing an immune response to the donor graft that can lead to immunological corneal graft rejection.

Currently, there is no therapy available. Gene Signal is working on new ways to prevent this syndrome. With its antisense oligonucleotide approach, it aims to block the pathways leading to the formation of blood vessels in the cornea. This approach uses short DNA fragments that specifically target and block the production of a protein that is required for the formation and growth of new blood vessels.

<
'/>"/>
SOURCE Gene Signal International SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Revealing the regulating mechanism behind signal transduction in the brain
2. Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment
3. Signalife Announces Anticipated Date of Transition to OTCBB
4. Signalife to Issue Breaking News Regarding Vianale & Vianale Tomorrow
5. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
6. AFL To Return to Oklahoma Due to Overwhelming Demand for Signalife Heart Screening
7. Signalife Board Approves Merger
8. Signalife Announces AFL Joins NIH Education Program
9. Signalife Appoints Lee Ehrlichman President and Chief Operating Officer
10. Signalife Appoints Lee Ehrlichman as Company Director and Operations Director; Additional Notice Received From Amex Regarding Sharholders Equity Deficiency
11. Signalife Awarded New U.S. Patent, System For, And Method Of, Monitoring Heartbeats Of A Patient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 Nearly 20,000 medical professionals and healthcare ... & Clinical Lab Expo in Chicago ... in diagnostic research and technology that will advance medicine ... As of Wednesday, July 30, more than 19,500 attendees ... Clinical Lab Expo, with more than 10,000 of these ...
(Date:7/31/2014)... the sound-processing part of the mouse brain in a ... trees in view. Their imaging technique allows zooming in ... and it enabled the team to watch brain cells ... results, which represent a step toward better understanding how ... the journal Neuron . , In the past, ...
(Date:7/31/2014)... , July 31, 2014 Rogne Bioscience, a ... Bay Area , has acquired a licence to ... commercialisation company. The potent anti-inflammatory activity of the peptides ... the University of Oxford,s Sir William Dunn School ... has raised over $1.5 million in seed financing, is ...
(Date:7/31/2014)... July 31, 2014 Research and Markets ... Genomics Market 2014-2018" report to their offering. ... is the study of the genetic material or genomes ... strong basis for the discovery and development of diagnostic ... or health conditions. Genomics is supported by three major ...
Breaking Biology Technology:Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3New mapping approach lets scientists zoom in and out as the brain processes sound 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... Biosciences,Corporation (Nasdaq: MATK ) today announced that ... Wilmington, Delaware, has ruled on various,post-trial motions and ... the defendants in the patent infringement suit brought ... Nutrition Specialties &,Food Ingredients GmbH. The suit involves ...
... Nov. 1 ThermoGenesis,Corp. (Nasdaq: KOOL ), a ... store, and administer therapeutic doses of,adult stem cells for ... financial results for the fiscal first quarter ended September,30, ... Call and Webcast Management will host a conference ...
... technical feasibility of ... ... TSX symbol: SBS, CALGARY, Nov. 1 /PRNewswire-FirstCall/ - ... for metabolic and cardiovascular diseases, today announced its,2007 third quarter operational ...
Cached Biology Technology:Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge 2Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge 3ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007 2ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007 3SemBioSys announces 2007 third quarter results 2SemBioSys announces 2007 third quarter results 3SemBioSys announces 2007 third quarter results 4SemBioSys announces 2007 third quarter results 5SemBioSys announces 2007 third quarter results 6SemBioSys announces 2007 third quarter results 7SemBioSys announces 2007 third quarter results 8SemBioSys announces 2007 third quarter results 9SemBioSys announces 2007 third quarter results 10SemBioSys announces 2007 third quarter results 11SemBioSys announces 2007 third quarter results 12
(Date:7/31/2014)... study (HPV-023; NCT00518336) shows the sustained efficacy, ... virus (HPV) vaccine Cervarix. Women vaccinated with ... more than nine years, and vaccine efficacy ... is the longest follow-up report for a ... for the full paper. , HPV ...
(Date:7/31/2014)... 100 percent of animal models against the highly infectious ... an intestinal disease that kills approximately 30,000 Americans annually. ... Infection and Immunity . , In the study, ... the purified toxins produced by C. difficile , ... laboratory model that mimics the human disease, after only ...
(Date:7/31/2014)... that the U.S. surgeon general issued a 101-page report ... State University published a paper breaking new ground on ... responds when exposed to ultraviolet (UV) light. , ... the UV rays found in sunlight. This damage can ... diseases. , "Our paper advances foundational knowledge about ...
Breaking Biology News(10 mins):Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3C. difficile vaccine proves safe, 100 percent effective in animal models 2New paper describes how DNA avoids damage from UV light 2New paper describes how DNA avoids damage from UV light 3
... Hold the Key to Muscular Dystrophy , A mutation ... been known to be associated with muscular dystrophy, but ... unknown. Lorenzo Puri, M.D., Ph.D. and colleagues have discovered ... amount of the histone deacetylase enzyme, HDAC2. Increased HDAC2 ...
... ever wondered why it seems like the littlest things make ... a spilled glass of water can lead to a fist ... three words to explain why people may be evolutionarily inclined ... sex. Although hostility or belligerent acts might not immediately ...
... long known that dinosaurs had tiny brains, but they had ... new study by Ohio University researchers Lawrence Witmer and Ryan ... heads than expected. By using CT scans, the scientists were ... show a clearer picture of the physiology of the airways. ...
Cached Biology News:The Burnham buzz 2U of Minnesota researcher finds link between aggression, status and sex 2CT scans reveal that dinosaurs were airheads 2CT scans reveal that dinosaurs were airheads 3
More cell-permeant than acridine orange....
HistoScan HRP Kit Universal Goat Kit...
4',6-Diamidino-2-phenylindole dihydrochloride...
...
Biology Products: